The new 2.4 billion Euro European Innovative Health Initiative (IHI) aims for more cooperation across sector boundaries. Parties in Pharma, Medtech, BioTech, AI and imaging will work together with patients. Finding the right partners for your IHI proposal can be challenging. With more than 10 years of experience, ttopstart can help you.
There is an urgent need for an innovative, more integrated approach to health research and healthcare. Future breakthroughs in medical science will involve cross-sectoral discoveries, such as medical device/drug combinations or diagnostics based on artificial intelligence.
The number of participating sector organisations in IHI is, therefore, larger and broader than in IMI. In addition to the main IMI partner EFPIA (European Federation of Pharmaceutical Industries and Associations) new partners Vaccines Europe, COCIR (medical imaging, radiotherapy, health ICT and electromedical industries), EuropaBio (biotechnology industry) and MedTech Europe (medical technology industry) will co-fund the programme.
How can we help you
We strongly believe in IHI’s strategy to further cross-sectoral innovations, which in the end will have a real and sustainable impact on patient and patient care. But how do you find the right consortium partners in these sectors that are still often isolated? How do you ensure that you are at the right table on time? How do you align your goals with those of others?’ ttopstart has more than 10 years of experience in bringing together partners, in particular in IMI projects. And we developed a set of ‘best practices’ to keep all your consortium partners engaged and focused on the real impact for patients. Have a look at our client stories
The end of April 2022, IHI published draft topics, which will help you to start on time to work on your proposal and look for partners.
- Innovative patient-facing care pathways for patients with neurodegenerative diseases and comorbidities
- Next generation imaging and image-guided diagnosis and therapy for cancer
- Precision oncology: Innovative patient-centric, multi-modal therapies against cancer
- Access and integration of heterogeneous health data for improved health care in diseases areas of high unmet public health need.
- New tools for prediction, prevention and monitoring of cardio-metabolic diseases including secondary manifestations to enable timely intervention
- Strengthening EU clinical development excellence and innovation attractiveness: Harmonized methodology to promote the uptake of early feasibility studies (EFS)
Like IMI, IHI will run open, competitive Calls for proposals. It will continue to publish draft topic texts before the Call launch to give applicants additional time to work on proposals.
is a multi-national project and aims at scaling-up biodegradable nanomedicines for multimodal precision cancer immunotherapy.
is an IMI-funded project that aims to set up a sustainable and flexible platform for molecular imaging of immune cell dynamics using a broad range of novel tracer strategies.
BIGPICTURE: the biggest database of pathology images to accelerate the development of artificial intelligence in medicine.
BIGPICTURE: The biggest database of pathology imagesWith the growing competitiveness in the funding arena, researchers are now more than ever expected to realise impact for science, industry and society. To take AI development in pathology to the next level, a...
One step closer to implementation of an extensive DNA test by ttopstart’s partner HMFLast week Nature published the paper “Pan-cancer whole genome analyses of metastatic solid tumors”. In this study, a team of leading Dutch scientists have created, for the first time,...
ttopstart responsible for the sustainability of IMI consortium ‘Immune-ImageAt ttopstart, we are really excited to contribute to Immune-Image. The Innovative Medicines Initiative (IMI) invests 30 Million Euro in research towards novel tracer strategies for clinical...